Combo of RG6146/venetoclax/rituximab for R/R DLBCL: initial data

Venetoclax, lenalidomide + rituximab: a chemotherapy-free regimen for previously untreated MCLПодробнее

Venetoclax + rituximab for R/R CLL: 7-year results of the MURANO trialПодробнее

Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimensПодробнее

REDLAMP 12: Lenalidomide & Rituximab Combo Promising as Initial Treatment for Mantle Cell LymphomaПодробнее

Novel combination therapies for the treatment of non-Hodgkin lymphomaПодробнее

Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?Подробнее

Acalabrutinib plus venetoclax and rituximab in the treatment of MCLПодробнее

RG6146 and venetoclax in DLBCLПодробнее

Addition of venetoclax to lenalidomide and rituximab in patients with untreated MCLПодробнее

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCLПодробнее

Venetoclax, lenalidomide and rituximab in R/R MCLПодробнее

LOTIS-9 trial design: loncastuximab tesirine plus rituximab in elderly patients with DLBCLПодробнее

Tazemetostat in combination with lenalidomide and rituximab for R/R follicular lymphomaПодробнее

Phase 2 Study of Acalabrutinib-Lenalidomide-Rituximab in Untreated Mantle Cell Lymphoma PatientsПодробнее

Dr. Crilley on the Addition of Rituximab to Lymphoma TreatmentПодробнее

Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphomaПодробнее

Key novel agents for relapsed diffuse large B-cell lymphomaПодробнее

Smart Start for newly diagnosed DLBCL: rituximab/lenalidomide/ibrutinibПодробнее

Improving outcomes for R/R DLBCL with polatuzumab vedotinПодробнее